Pentoxifylline suppresses renal tumour necrosis factor- and ameliorates experimental crescentic glomerulonephritis in rats
Open Access
- 19 February 2004
- journal article
- research article
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 19 (5) , 1106-1115
- https://doi.org/10.1093/ndt/gfh127
Abstract
Background. Crescentic glomerulonephritis is a rapidly progressive form of glomerulonephritis, but treatment remains non-specific. The methylxanthine derivative pentoxifylline (PTX) is a clinically available phosphodiesterase inhibitor with anti-inflammatory and immunoregulatory activities. This study examined whether PTX has beneficial effects in a rat model of anti-glomerular basement membrane (GBM) crescentic glomerulonephritis. Methods. Experimental crescentic glomerulonephritis was induced in Wistar rats by intravenous injection of rabbit anti-rat GBM serum and treated with either vehicle (phosphate-buffered saline) or PTX (0.1 g/kg/day) intravenously on a daily basis. Groups of six animals were euthanized at days 3, 7, 14 or 28 after induction of disease. Effects of PTX on renal function, histology and expression of cytokines, chemokines and adhesion molecules were determined. Results. Compared with the vehicle-treated nephritic rats, PTX treatment beginning at the start of the nephritis significantly suppressed mRNA expression of tumour necrosis factor (TNF)-α, but not interleukin-1β, throughout the course of nephritis. Moreover, PTX decreased renal mRNAs for intercellular adhesion molecule-1 (ICAM-1), monocyte chemoattractant protein-1 (MCP-1), regulated on activation, normal T-cell expressed and secreted (RANTES) and osteopontin (OPN) at all time points examined. These effects were associated with a significant inhibition of macrophage and T-cell infiltration, a reduction of 24-h urinary protein excretion (50–75%, PPConclusions. PTX is an effective anti-inflammatory and immunomodulatory agent capable of suppressing rat crescentic glomerulonephritis. Inhibition of renal TNF-α, ICAM-1, RANTES, MCP-1 and OPN expression may be a mechanism whereby PTX suppresses progressive renal injury in rat crescentic glomerulonephritis.Keywords
This publication has 24 references indexed in Scilit:
- Monocyte chemoattractant protein-1 and osteopontin differentially regulate monocytes recruitment in experimental glomerulonephritisKidney International, 2001
- Prevention and treatment of experimental crescentic glomerulonephritis by blocking tumour necrosis factor‐αNephrology Dialysis Transplantation, 2001
- Pentoxifylline attenuates experimental mesangial proliferative glomerulonephritisKidney International, 1999
- Pentoxifylline Inhibits PDGF-induced Proliferation of and TGF-β-stimulated Collagen Synthesis by Vascular Smooth Muscle CellsJournal of Molecular and Cellular Cardiology, 1999
- De novo glomerular osteopontin expression in rat crescentic glomerulonephritisKidney International, 1998
- Differential regulation of TNFα, IL-1β, IL-6, IL-8, TNFβ, and IL-10 by pentoxifyllineInternational Journal of Immunopharmacology, 1996
- Elevated Cyclic AMP Inhibits NF-κB-mediated Transcription in Human Monocytic Cells and Endothelial CellsJournal of Biological Chemistry, 1996
- Interleukin-1 receptor antagonist halts the progression of established crescentic glomerulonephritis in the ratKidney International, 1995
- The specific type IV phosphodiesterase inhibitor rolipram suppresses tumor necrosis factor-α production by human mononuclear cellsInternational Journal of Immunopharmacology, 1993
- Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxofyllineBiochemical and Biophysical Research Communications, 1988